IDT Australia FY22 Interim Results and Investor Update

• H1 FY`22: Revenue year-on-year increase of 74% to $8.56 million, EBITDA of $1.97 million and $1.21 million Profit • H1 FY`22 closing cash balance of $13.31 million Sterile Manufacturing Licence Secured From The Therapeutic Goods Administration • Successfully executed the Letter Agreement with the Australian Government, Department of Health, to bring IDT’s cGMP sterile manufacturing facility into